
CLAIMS

What is claimed is:

1. A compound having the Formula **I**:



(I);

or a pharmaceutically acceptable salt thereof, wherein











R^a is $C_{2\text{-}4}$alkyl or monocyclic $C_{3\text{-}6}$ cycloalkyl; and





R^b is $C_{1\text{-}4}$alkyl.

2. The compound of claim 1, wherein R^a is ethyl, isopropyl, or cyclopropyl.


3. The compound of claim 1 or 2, wherein R^b is methyl or ethyl.

4. The compound of claim 1, wherein the compound is selected from the group consisting of:


,

,

,

,

,

,

,

,

,

,


,

,

,

, or a pharmaceutically acceptable salt thereof.

5. A compound having the Formula **II**:


(**II**);

or a pharmaceutically acceptable salt thereof, wherein

R^a is C_{1-4}alkyl;

R^b is C_{1-4}alkyl; and

R^c is hydrogen or C_{1-4}alkyl.

6. The compound of claim 5, wherein R^a is methyl or ethyl.





7. The compound of claim 5 or 6, wherein R^b is methyl, ethyl, or isopropyl.









8. The compound of any one of claims 5-7, wherein R^c is hydrogen or methyl.

9. The compound of any one of claims 5-8, wherein R^c is hydrogen.





10. The compound of any one of claims 5-8, wherein R^c is methyl.







11. The compound of claim 5, wherein the compound is selected from the group consisting of:


,

,

,

,


,

,

,

,

,

,

, and

, or a pharmaceutically acceptable salt thereof.

12. A compound selected from the group consisting of:


,

,

,

,


,

,

,

,

, and

or a pharmaceutically acceptable salt thereof.

13. A pharmaceutical composition comprising a compound of any one of claims 1-12, or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable carrier.

14. A method of treating a condition relating to aberrant function of a sodium ion channel in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of any one of claims 1-12, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of claim 13.

15. The method of claim 14, wherein the condition is a neurological or psychiatric disorder.

16. The method of claim 14 or 15, wherein the condition is epilepsy or an epilepsy syndrome.

17. The method of any one of claims 14-16, wherein the condition is a genetic epilepsy or a genetic epilepsy syndrome.

18. The method of any one of claims 14-16, wherein the condition is a pediatric epilepsy or a pediatric epilepsy syndrome.

19. The method of any one of claims 14-16, wherein the condition is epileptic encephalopathy.

20. The method of claim 19, wherein the epileptic encephalopathy is selected from the group consisting of Dravet syndrome, infantile spasms, or Lennox-Gastaut syndrome.

21. The method of claim 14 or 15, wherein the condition is selected from the group consisting of epileptic encephalopathy, epileptic encephalopathy with SCN1A, SCN2A,

SCN8A mutations, early infantile epileptic encephalopathy, Dravet syndrome, Dravet syndrome with SCN1A mutation, generalized epilepsy with febrile seizures, intractable childhood epilepsy with generalized tonic-clonic seizures, infantile spasms, benign familial neonatal-infantile seizures, SCN2A epileptic encephalopathy, focal epilepsy with SCN3A mutation, cryptogenic pediatric partial epilepsy with SCN3A mutation, SCN8A epileptic encephalopathy, sudden unexpected death in epilepsy, Rasmussen encephalitis, malignant migrating partial seizures of infancy, autosomal dominant nocturnal frontal lobe epilepsy, sudden expected death in epilepsy (SUDEP), KCNQ2 epileptic encephalopathy, and KCNT1 epileptic encephalopathy.

22. A method of treating a neurological disorder or a psychiatric disorder, wherein the method comprises administering to a subject in need thereof the compound of any one of claims 1-12, or the pharmaceutically acceptable salt thereof, or a pharmaceutical composition of claim 13.

23. A method of treating a pain, wherein the method comprises administering to a subject in need thereof a compound of any one of claims 1-12, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of claim 13.

24. A method of treating or preventing a trigeminal autonomic cephalalgia (TAC) in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of any one of claims 1-12, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of claim 13, wherein the TAC is selected from the group consisting of paroxysmal hemicrania, hemicrania continua, short-lasting unilateral neuralgiform headache attacks with conjunctival injection and tearing (SUNCT), short-lasting unilateral neuralgiform headache attacks with cranial autonomic symptoms (SUNA), and long-lasting autonomic symptoms with hemicrania.

25. The method of claim 24, wherein the TAC is a short-lasting unilateral neuralgiform headache attack.

26. The method of claim 24 or 25, wherein the TAC is SUNCT.

27. The method of claim 24 or 25, wherein the TAC is SUNA.

28. The method of any one of claims 24-27, wherein the subject has an inadequate response to at least one medication used for the treatment of a TAC.

29. A method of treating or preventing a migraine in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of any one of claims 1-12, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of claim 13, wherein the migraine is selected from the group consisting of migraine without

aura, migraine with aura, familial hemiplegic migraine type 1 (FHM1), familial hemiplegic migraine type 2 (FHM2), familial hemiplegic migraine type 4 (FHM4), and sporadic hemiplegic migraine (SHM).

30. The method of claim 29, wherein the migraine is migraine without aura.

31. The method of claim 29, wherein the migraine is migraine with aura.

32. The method of claim 29, wherein the migraine is FHM1.

33. The method of claim 29, wherein the migraine is FHM2.

34. The method of claim 29, wherein the migraine is FHM4.

35. The method of claim 29, wherein the migraine is SHM.

36. The method of any one of claims 29-35, wherein the subject has an inadequate response to at least one medication used for the treatment of a migraine.

37. A method of treating or preventing cortical spreading depression (CSD) in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of any one of claims 1-12, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of claim 13.

38. A method of treating or preventing a cranial neuropathy or multiple cranial neuropathies in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of any one of claims 1-12, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of claim 13, wherein the cranial neuropathy is selected from the group consisting of bell palsy, microvascular cranial nerve palsy, third nerve palsy, fourth nerve palsy, and sixth nerve palsy.